In December 2021, the U.S. Food & Drug Administration (FDA) approved injectable cabotegravir (CAB PrEP) for use to reduce the risk of sexually-acquired HIV. On the heels of this exciting news, scientists, policymakers, and implementers around the world are working to make this long-acting HIV prevention option available in their countries.
In this webinar, we explore ongoing and completed research on CAB PrEP, learn about the recently released FDA guidance, and hear from a panel of implementers and policymakers on what is needed to advance introduction of this new HIV prevention product.
Watch the recording here.
*All recordings and webinar resources are available on PrEPWatch at Global PrEP Learning Network – PrEPWatch.